Research programme: tyrosine kinase inhibitor - Ascepion/DebiopharmAlternative Names: ASP-08126; Debio 1144
Latest Information Update: 16 Jul 2016
At a glance
- Originator Ascepion Pharmaceuticals
- Developer Ascepion Pharmaceuticals; Debiopharm
- Class Small molecules
- Mechanism of Action Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours